Real-world efficacy and safety of dolutegravir plus lamivudine versus tenofovir plus lamivudine and efavirenz in ART-naive HIV-1-infected adults

被引：7

作者：

Li, Jin ^{[1
]}

Chen, Dabiao ^{[2
]}

Wen, Zhiwei ^{[1
]}

Du, Yanzhang ^{[1
]}

Huang, Zhanlian ^{[2
]}

Zhong, Huijun ^{[1
]}

Wang, Yanhao ^{[1
]}

Yin, Sichun ^{[1
]}

机构：

[1] Ninth Peoples Hosp Dongguan, Dept Infect Dis, Dongguan, Peoples R China

[2] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Infect Dis, Guangzhou, Peoples R China

来源：

MEDICINE | 2022年 / 101卷 / 42期

关键词：

ART-naive; dolutegravir; DTG+3TC; dual therapy; HIV-1; DNA; lamivudine;

D O I：

10.1097/MD.0000000000031100

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Limited real-world data on dolutegravir (DTG) plus lamivudine (3TC) for HIV-1-infected individuals have been reported. This study aimed to evaluated the real-world efficacy and safety of DTG + 3TC in ART-naive HIV-1-infected adults in China. This real-world prospective observational cohort study enrolled HIV-1-infected adults receiving ART initiation with DTG + 3TC (D3 group) or tenofovir plus lamivudine and efavirenz (TDF + 3TC + EFV, TLE group) with subgroups of low viral load (LVL, <= 500,000 copies/mL) and high viral load (HVL, >500,000 copies/mL) according to baseline HIV-1 RNA. Efficacy were assessed by proportion of virologic suppression, changes of CD4(+) cell count and CD4/CD8 ratio, HIV-1 DNA decay, and safety by symptoms and changes of laboratory indicators at week 4, 12, 24, 36, and 48. Totally 45 participants in D3 group and 95 in TLE group were enrolled. The proportion of HIV RNA < 50 copies/mL were 48.7% (19/39), 84.6% (33/39), 100% (39/39), 100% (39/39) in D3-LVL subgroup at week 4, 12, 24, 48, compared with 1.3% (1/75), 14.7% (11/75), 86.7% (65/75), 96.0% (72/75) in TLE-LVL subgroup, with P < .05 at week 4, 12, and 36. The proportion were 0.0% (0/6), 66.7% (4/6), 83.3% (5/6), 100% (6/6) in D3-HVL subgroup compared with 0.0% (0/20), 5.0% (1/20), 85.0% (17/20), 100% (20/20) in TLE-HVL subgroup, with P < .05 at week 12. No virologic rebound was observed in D3 group. Mean change of CD4/CD8 ratio were higher in D3-LVL versus TLE-LVL subgroup at each scheduled visit (P < .05), while CD4(+) cell counts increased significantly in D3-HVL versus TLE-HVL subgroup at week 4 and 12 (P < .05). Less complaint of dizziness, insomnia, dreaminess and amnesia, lower elevated level of triglyceride and higher elevated level of creatinine from baseline to week 48 were documented in D3 group (P < .05). Total HIV-1 DNA decayed along with HIV-1 RNA after DTG + 3TC initiation in both D3-LVL and D3-HVL subgroups. DTG + 3TC achieved virological suppression more rapidly and stably versus TDF + 3TC + EFV in ART-naive HIV-1-infected adults, with better immunological response and less adverse drug effect, and reduced total HIV-1 DNA effectively. DTG + 3TC is a potent regimen for ART-naive individuals with HIV-1 infection.

引用

页数：7

共 28 条

[1]

AIDS and Hepatitis C Professional Group Society of Infectious Diseases Chinese Medical Association, 2021, Zhonghua Nei Ke Za Zhi, V60, P1106, DOI 10.3760/cma.j.cn112138-20211006-00676

[2]

AIDS and Hepatitis C Professional Group Society of Infectious Diseases Chinese Medical Association, 2018, Zhonghua Nei Ke Za Zhi, V57, P867, DOI 10.3760/cma.j.issn.0578-1426.2018.12.002

[3] Long-term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multi-centre cohort of HIV-1-infected, virologically suppressed patients [J].

Baldin, Gianmaria ;

Ciccullo, Arturo ;

Rusconi, Stefano ;

Capetti, Amedeo ;

Sterrantino, Gaetana ;

Colafigli, Manuela ;

d'Ettorre, Gabriella ;

Giacometti, Andrea ;

Cossu, Maria Vittoria ;

Borghetti, Alberto ;

Gennari, William ;

Mussini, Cristina ;

Borghi, Vanni ;

Di Giambenedetto, Simona .

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2019, 54 (06) :728-734

[4] Quantification of Total HIV DNA as a Marker to Measure Viral Reservoir: Methods and Potential Implications for Clinical Practice [J].

Belmonti, Simone ;

Di Giambenedetto, Simona ;

Lombardi, Francesca .

DIAGNOSTICS, 2022, 12 (01)

[5] HIV-1 DNA Decay Dynamics in Blood During More Than a Decade of Suppressive Antiretroviral Therapy [J].

Besson, Guillaume J. ;

Lalama, Christina M. ;

Bosch, Ronald J. ;

Gandhi, Rajesh T. ;

Bedison, Margaret A. ;

Aga, Evgenia ;

Riddler, Sharon A. ;

McMahon, Deborah K. ;

Hong, Feiyu ;

Mellors, John W. .

CLINICAL INFECTIOUS DISEASES, 2014, 59 (09) :1312-1321

[6] Efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multicentre cohort of patients with suppressed HIV-1 replication [J].

Borghetti, A. ;

Baldin, G. ;

Lombardi, F. ;

Ciccullo, A. ;

Capetti, A. ;

Rusconi, S. ;

Sterrantino, G. ;

Latini, A. ;

Cossu, M. V. ;

Gagliardini, R. ;

De Luca, A. ;

Di Giambenedetto, S. .

HIV MEDICINE, 2018, 19 (07) :452-454

[7] Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice [J].

Borghetti, Alberto ;

Lombardi, Francesca ;

Gagliardini, Roberta ;

Baldin, Gianmaria ;

Ciccullo, Arturo ;

Moschese, Davide ;

Emiliozzi, Arianna ;

Belmonti, Simone ;

Lamonica, Silvia ;

Montagnani, Francesca ;

Visconti, Elena ;

De Luca, Andrea ;

Di Giambenedetto, Simona .

BMC INFECTIOUS DISEASES, 2019, 19 (1)

[8] Clinical benefit of dolutegravir in HIV-1 management related to the high genetic barrier to drug resistance [J].

Brenner, Bluma G. ;

Wainberg, Mark A. .

VIRUS RESEARCH, 2017, 239 :1-9

[9] Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy - naive adults with HIV-1 infection [J].

Cahn, Pedro ;

Sierra Madero, Juan ;

Arribas, Jose R. ;

Antinori, Andrea ;

Ortiz, Roberto ;

Clarke, Amanda E. ;

Hung, Chien-Ching ;

Rockstroh, Juergen K. ;

Girard, Pierre-Marie ;

Sievers, Jorg ;

Man, Choy Y. ;

Urbaityte, Rimgaile ;

Brandon, Daisy J. ;

Underwood, Mark ;

Pappa, Keith A. ;

Curtis, Lloyd ;

Smith, Kimberly Y. ;

Gartland, Martin ;

Aboud, Michael ;

van Wyk, Jean ;

Wynne, Brian .

AIDS, 2022, 36 (01) :39-48

[10] Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials [J].